The company’s portfolio shift is anchored by the successful integration of microneedle radiofrequency (MNRF) and dermabrasion systems alongside its traditional high-intensity focused ultrasound (HIFU) and monopolar radiofrequency (MRF) platforms. As of June, Classys reported over 22,000 HIFU installations and 4,000 MRF units, while the newer MNRF and dermabrasion lines have each surpassed 6,000 units globally. This footprint serves as a critical engine for recurring revenue, with consumables sales reaching 80.2 billion KRW in the first half of 2026, marking a 52.7% increase from the same period two years prior.
Classys Targets 50,000 Global Device Milestone
With global reach expanding beyond its core ultrasound and radiofrequency offerings, Seoul-based Classys Inc. expects its total cumulative device sales to eclipse 50,000 units by year-end. This growth trajectory reflects a strategic pivot toward a diversified aesthetic portfolio, bolstered by a 29% surge in first-half export sales.
Financial performance remains robust, with consolidated revenue hitting 192.7 billion KRW for the first half of the year, a 20% year-over-year climb. Even excluding the consolidation of its Brazilian subsidiary, the company maintained an operating margin of 50.8%. Looking ahead, management plans to leverage its established clinical networks and distributor partnerships to roll out next-generation platforms like Quadessy and the upcoming European launch of the Viclara dermabrasion system. By focusing on localized marketing and combination treatment protocols, Classys aims to deepen its presence in key markets including the UK, Sweden, and the Netherlands while maximizing the utility of its existing installed base.
Comments (0)
No comments yet. Be the first!